MX2012010448A - Conjugados de carbohidrato-poli aminoacido-farmaco. - Google Patents

Conjugados de carbohidrato-poli aminoacido-farmaco.

Info

Publication number
MX2012010448A
MX2012010448A MX2012010448A MX2012010448A MX2012010448A MX 2012010448 A MX2012010448 A MX 2012010448A MX 2012010448 A MX2012010448 A MX 2012010448A MX 2012010448 A MX2012010448 A MX 2012010448A MX 2012010448 A MX2012010448 A MX 2012010448A
Authority
MX
Mexico
Prior art keywords
carbohydrate
drug conjugates
polyamino acid
polymer conjugate
compositions
Prior art date
Application number
MX2012010448A
Other languages
English (en)
Inventor
Van Sang
Mohammad Ahmadian
Wendy Taylor
Lei Yu
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of MX2012010448A publication Critical patent/MX2012010448A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Aquí se describen composiciones que incluyen un conjugado de polímero y glucosamina asociada operativamente con el conjugado de polímero, en donde el conjugado de polímero incluye un primer fármaco. También se describen métodos de uso de dichas composiciones para tratar, para mejorar, o para diagnosticar una enfermedad o una condición tal como cáncer.
MX2012010448A 2010-03-11 2011-03-09 Conjugados de carbohidrato-poli aminoacido-farmaco. MX2012010448A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31298110P 2010-03-11 2010-03-11
PCT/US2011/027773 WO2011112733A1 (en) 2010-03-11 2011-03-09 Carbohydrate-polyamino acid-drug conjugates

Publications (1)

Publication Number Publication Date
MX2012010448A true MX2012010448A (es) 2012-12-05

Family

ID=44560542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010448A MX2012010448A (es) 2010-03-11 2011-03-09 Conjugados de carbohidrato-poli aminoacido-farmaco.

Country Status (11)

Country Link
US (1) US20110224148A1 (es)
EP (1) EP2544720A1 (es)
JP (1) JP2013522220A (es)
KR (1) KR20130008034A (es)
CN (1) CN102811742A (es)
AU (1) AU2011224374A1 (es)
BR (1) BR112012022337A2 (es)
CA (1) CA2791399A1 (es)
MX (1) MX2012010448A (es)
TW (1) TW201132357A (es)
WO (1) WO2011112733A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206736B1 (en) 2005-12-05 2012-02-08 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
ES2430380T3 (es) 2007-05-09 2013-11-20 Nitto Denko Corporation Composiciones que incluyen un compuesto hidrófobo y un conjugado de poliaminoácido
RU2011117935A (ru) * 2008-10-15 2012-11-27 Нитто Денко Корпорейшн Способ получения конъюгатов полиглутаматов
ES2677478T3 (es) 2012-04-12 2018-08-02 Nitto Denko Corporation Conjugados de copolímero
EP2846838B1 (en) * 2012-05-07 2017-05-03 Nitto Denko Corporation Polymer conjugates with a linker
WO2014175898A1 (en) * 2013-04-26 2014-10-30 Nitto Denko Corporation A large scale process for preparing poly (glutamyl-glutamate) conjugates
KR101471890B1 (ko) * 2013-05-13 2014-12-12 한국원자력의학원 NOTA 표지 글루코사민-함유 시클로 RGDfK 유도체, 그 제조방법 및 그것을 포함하는 핵의학 영상 조영제 및 암 치료제
KR101471891B1 (ko) * 2013-05-13 2014-12-12 한국원자력의학원 DOTA 표지 글루코사민-함유 시클로 RGDfK 유도체, 그 제조방법 및 그것을 포함하는 핵의학 영상 조영제 및 암 치료제
KR101494429B1 (ko) 2013-05-13 2015-02-24 한국원자력의학원 NODAGA 표지 글루코사민-함유 시클로 RGDfK 유도체, 그 제조방법 및 그것을 포함하는 핵의학 영상 조영제 및 암 치료제
CN105693544B (zh) * 2016-03-04 2018-02-23 华东师范大学 用于抗肿瘤药物递送的小分子材料及制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG147286A1 (en) * 1999-10-12 2008-11-28 Cell Therapeutics Inc Manufacture of polyglumate-therapeutic agent conjugates
CA2402643A1 (en) * 2000-03-17 2001-09-27 Cell Therapeutics, Inc. Polyglutamic acid-camptothecin conjugates and methods of preparation
DE202005011124U1 (de) * 2005-07-12 2005-12-01 Shirzadi, Houtan, Dr. Mundhygienemittel für die Reinigung von Brückenzahnersatz
EP2206736B1 (en) * 2005-12-05 2012-02-08 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
CA2716662A1 (en) * 2008-03-06 2009-03-11 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer

Also Published As

Publication number Publication date
CN102811742A (zh) 2012-12-05
KR20130008034A (ko) 2013-01-21
WO2011112733A1 (en) 2011-09-15
US20110224148A1 (en) 2011-09-15
AU2011224374A1 (en) 2012-09-27
CA2791399A1 (en) 2011-09-15
TW201132357A (en) 2011-10-01
EP2544720A1 (en) 2013-01-16
BR112012022337A2 (pt) 2016-07-05
JP2013522220A (ja) 2013-06-13

Similar Documents

Publication Publication Date Title
MX2012010448A (es) Conjugados de carbohidrato-poli aminoacido-farmaco.
MX2013010286A (es) Conjugados de amatoxinas con enlaces mejorados.
BR112015011118A2 (pt) conjugado; composição farmacêutica; e uso de um ou mais dos conjugados
MX2013003452A (es) Conjugados de amatoxina con enlazantes mejorados.
MX366955B (es) Crlx101 para usarse en el tratamiento de cáncer.
MY173826A (en) Oligonucleotide conjugates
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
MX2018013332A (es) Conjugados de pirrolobenzodiazepina diana.
WO2011139348A3 (en) Uses of phospholipid conjugates of synthetic tlr7 agonists
EP2910573A4 (en) CONJUGATED ANTIBODY-MEDICINAL PRODUCT PRODUCED BY CONNECTION THROUGH A LINK HAVING A HYDROPHILIC STRUCTURE
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
CR20120202A (es) Métodos y composiciones para tratar cáncer
IN2015DN00694A (es)
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
MX345514B (es) Composiciones pesticidas.
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
IL218523A0 (en) Extracellular targeted drug conjugates
EA032867B9 (ru) Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты
IN2014MN01819A (es)
MX2011003738A (es) Conjugados hpma-docetaxel o gemcitabine y sus usos asociados.
WO2013103301A3 (en) Method for preparing cell targeting conjugates, and the complexes obtained
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents

Legal Events

Date Code Title Description
FA Abandonment or withdrawal